Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Melphalan Flufenamide→

Melphalan Flufenamide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
380449-51-4
Molecular formula
C24H30Cl2FN3O3
Molecular weight
498.4 g/mol
Drug class
Peptide-conjugated alkylating antineoplastic agentmelphalan prodrug-like peptide conjugate
Mechanism of action
Melphalan flufenamide is a peptide-conjugated alkylating agent designed to be taken up by cells and cleaved by intracellular peptidases to release melphalan. Melphalan alkylates DNA, causing DNA crosslinking and inhibition of DNA synthesis and tumour-cell proliferation.
Indications / reported uses
  • Historical US indication: in combination with dexamethasone for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy and refractory to specified prior agents. US approval was withdrawn effective 23 February 2024; do not present it as a current US-authorised treatment.

Sources: Federal Register — FDA final decision withdrawing PEPAXTO approval, 18 April 2024 · FDA Orphan Drug database — Melphalan flufenamide · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Melphalan Flufenamide Environmental Risk Assessment (ERA) (the Melphalan Flufenamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.